CareDx, Inc (NASDAQ:CDNA) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP reduced its position in CareDx, Inc (NASDAQ:CDNA - Free Report) by 14.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 165,362 shares of the company's stock after selling 28,360 shares during the period. Wellington Management Group LLP owned about 0.31% of CareDx worth $3,540,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quarry LP purchased a new position in shares of CareDx during the 3rd quarter worth approximately $27,000. Thompson Davis & CO. Inc. increased its position in CareDx by 6.3% during the fourth quarter. Thompson Davis & CO. Inc. now owns 16,050 shares of the company's stock worth $344,000 after buying an additional 950 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of CareDx by 6.5% in the fourth quarter. Principal Financial Group Inc. now owns 18,984 shares of the company's stock worth $406,000 after acquiring an additional 1,151 shares during the last quarter. Plato Investment Management Ltd lifted its position in shares of CareDx by 34.1% in the fourth quarter. Plato Investment Management Ltd now owns 5,390 shares of the company's stock valued at $116,000 after acquiring an additional 1,370 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of CareDx by 1.8% during the fourth quarter. Rhumbline Advisers now owns 81,201 shares of the company's stock valued at $1,738,000 after acquiring an additional 1,451 shares during the last quarter.

CareDx Price Performance

NASDAQ:CDNA traded up $0.26 during trading hours on Tuesday, reaching $19.16. 460,383 shares of the company were exchanged, compared to its average volume of 856,237. CareDx, Inc has a 52-week low of $7.42 and a 52-week high of $34.84. The stock has a 50 day simple moving average of $20.13 and a 200 day simple moving average of $22.62. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -7.10 and a beta of 2.18.

Remove Ads

CareDx (NASDAQ:CDNA - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share for the quarter, beating analysts' consensus estimates of $0.05 by $1.46. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The firm had revenue of $86.58 million for the quarter, compared to analysts' expectations of $84.56 million. On average, analysts predict that CareDx, Inc will post -0.9 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on CDNA. Stephens reissued an "overweight" rating and issued a $40.00 target price on shares of CareDx in a research note on Thursday, February 27th. StockNews.com raised shares of CareDx from a "hold" rating to a "buy" rating in a research report on Wednesday, February 26th. HC Wainwright decreased their target price on shares of CareDx from $26.00 to $25.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. Finally, Wells Fargo & Company upgraded CareDx from an "underweight" rating to an "equal weight" rating and cut their price target for the company from $28.00 to $24.00 in a report on Wednesday, January 15th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, CareDx has a consensus rating of "Moderate Buy" and an average price target of $31.83.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.